替考拉宁联合替加环素治疗重症腹腔感染的临床效果  

Clinical effects of teicoplanin combined with tigecycline in the treatment of severe abdominal infections

作　　者：刘国生 杜伟程 郑燕梅 尤德源 LIU Guosheng;DU Weicheng;ZHENG Yanmei;YOU Deyuan(Department of Critical Care Medicine,the Second Affiliated Hospital of Fujian Medical University,Fujian Province,Quanzhou 362000,China)

机构地区：[1]福建医科大学附属第二医院重症医学科,福建省泉州市362000

出　　处：《临床合理用药杂志》2024年第29期16-19,共4页Chinese Journal of Clinical Rational Drug Use

摘　　要：目的观察替考拉宁联合替加环素治疗重症腹腔感染的临床效果。方法选择2020年3月—2022年6月福建医科大学附属第二医院收治的重症腹腔感染患者80例,采用抽签法随机分为研究组和对照组,每组40例。对照组采用替加环素治疗,研究组在对照组的基础上联合替考拉宁治疗,2组均治疗14 d。比较2组临床疗效,治疗前后生命体征、血常规、炎性指标及不良反应。结果研究组总有效率(95.00%)较对照组(75.00%)高(χ^(2)=6.275,P=0.012)。治疗14 d后,2组体温、心率、呼吸频率及白细胞计数较治疗前降低,血红蛋白水平及血小板计数较治疗前升高,且研究组降低/升高幅度大于对照组(P<0.05或P<0.01);2组降钙素原、C反应蛋白、白介素-6、肿瘤坏死因子-α水平较治疗前降低,白介素-10水平较治疗前升高,且研究组降低/升高幅度大于对照组(P<0.01)。研究组不良反应总发生率为7.50%,与对照组的15.00%比较差异无统计学意义(χ^(2)=1.127,P=0.288)。结论对重症腹腔感染患者采用替考拉宁联合替加环素治疗的效果较好,可改善患者的生命体征,有效控制炎性反应,且不良反应发生率低,安全性高。Objective To observe the clinical effects of teicoplanin combined with tigecycline in the treatment of severe abdominal cavity infection.Methods Eighty patients with severe abdominal cavity infection admitted to the Second Hospital of Fujian Medical University from March 2020 to June 2022 were selected,and they were randomly divided into the study group and the control group by lottery method,40 cases in each group.The control group was treated with tigecycline,and the study group was treated with teicoplanin on the basis of the control group,and both groups were treated for 14 days.The clinical efficacy,and the vital signs,blood counts,inflammatory indexes before and after treatmentand,adverse reactions of the two groups were compared.Results The total effective rate of the study group(95.00%)was higher than that of the control group(75.00%)(χ^(2)=6.275,P=0.012).After 14 days of treatment,body temperature,heart rate,respiratory rate and WBC counts in the two groups were lower and Hb levels and PLT counts were higher than before treatment,and the magnitude of decrease/increase in the study group was greater than that in the control group(P<0.05 or P<0.01).PCT,CRP,IL-6 and TNF-αlevels were lower and IL-10 levels were higher than before treatment in both groups,and the magnitude of decrease/increase in the study group was greater than that in the control group(P<0.01).The total incidence of adverse reactions in the study group was 7.50%,and the difference was not statistically significant compared with 15.00%in the control group(χ^(2)=1.127,P=0.288).Conclusion The effect of teicoplanin combined with tigecycline in patients with severe abdominal cavity infection is better,which can improve the vital signs of patients,effectively control the inflammatory reaction,and the incidence of adverse reactions is low,and the safety is high.

关 键 词：腹腔感染 重症 替考拉宁 替加环素 临床疗效 炎性反应 

分 类 号：R619.3[医药卫生—外科学]